Akero Therapeutics Q1 EPS $(0.90) Beats $(0.95) Estimate
Portfolio Pulse from Benzinga Newsdesk
Akero Therapeutics reported Q1 EPS losses of $(0.90), surpassing the analyst consensus estimate of $(0.95) by 5.26%. However, this represents a 63.64% increase in losses compared to $(0.55) per share from the same period last year.

May 10, 2024 | 11:15 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Akero Therapeutics' Q1 earnings report showed smaller-than-expected losses, but an increase in losses year-over-year.
While beating EPS estimates typically has a positive impact on stock prices, the significant increase in losses year-over-year could temper investor enthusiasm. The mixed results present a neutral outlook in the short term as investors weigh the better-than-expected performance against the increased losses.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100